SCHEMBL2006208

SCHEMBL2006208

C=CCn1c(-c2ccc(OCCCC3CCNC3)cc2)nc2ncccc2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
HCAR2 Q8TDS4 5/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
ADRA1A P35348 3/20 0.36
KCNH2 Q12809 3/20 0.36
HRH3 Q9Y5N1 3/20 0.36
PDE6D O43924 2/20 0.36
NPY1R P25929 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
POLB P06746 1/20 0.35
AVPR1B P47901 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006210 0.79 KDM4E (0.37) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL2003132 0.79 HRH3 (0.58) DRD2DRD3ADRA1AKCNH2HRH3
SCHEMBL5258160 0.72 KCNH2 (0.51) ADORA3ADORA2AADORA2BADORA1ADRA1A
SCHEMBL5026023 0.70 IDO1 (0.50) KDM4EALDH1A1HPGDSMN1; SMN2RXFP1
SCHEMBL4053680 0.69 HRH3 (0.61) KDM4EALDH1A1HPGDSMN1; SMN2HRH3
SCHEMBL5258954 0.68 KCNH2 (0.52) ADORA3ADORA2AADORA2BADORA1ADRA1A
SCHEMBL7956507 0.66 ITGB3 (0.46) HRH3NPY1R
SCHEMBL4055490 0.65 HRH3 (0.56) ADRA1AKCNH2HRH3MAPT
SCHEMBL4057662 0.64 HRH3 (0.61) KDM4EALDH1A1HPGDSMN1; SMN2HRH3
SCHEMBL935709 0.64 NPY1R (0.50) NPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US claimed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US claimed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP claimed
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 DRD2 925/4885DRD3 583/4885ADORA3 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.